Pricing Log in Create free account
Friday 6 November 2026 Export RYTM’s income statement to Excel — free account

Rhythm Pharmaceuticals, Inc.

RYTM Healthcare Biotechnology

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue
+79.6%
EPS
+26.9%
Free cash flow
+95.4%

Quarter to September 2026, against a year earlier

112.38 7.36 +7.01%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
6/9
Altman Z
15.89
Beneish M
−2.93
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Rhythm Pharmaceuticals, Inc. 8-K filed Jan 9, 2026

Period ended Jan 9, 2026 · Filed · accepted 9:06 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release